Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedra Ban Effective In April; FDA Will Follow-Up On Internet Firms

This article was originally published in The Tan Sheet

Executive Summary

A 1final rule prohibiting the sale of dietary supplements containing ephedrine alkaloids will become effective April 12, FDA announced Feb. 6

You may also be interested in...



Ephedra Imports Legal While Nutraceutical Appeal Underway – Emord

FDA's refusal to allow Hong Kong-based broker EMAX to import ephedra-containing dietary supplements into the U.S. violates an April 2005 court ruling which invalidated the agency's ban on the botanical, according to a lawsuit filed April 21 by the firm Emord & Associates

Ephedra Imports Legal While Nutraceutical Appeal Underway – Emord

FDA's refusal to allow Hong Kong-based broker EMAX to import ephedra-containing dietary supplements into the U.S. violates an April 2005 court ruling which invalidated the agency's ban on the botanical, according to a lawsuit filed April 21 by the firm Emord & Associates

Ephedra Imports Legal While Nutraceutical Appeal Underway – Emord

FDA's refusal to allow Hong Kong-based broker EMAX to import ephedra-containing dietary supplements into the U.S. violates an April 2005 court ruling which invalidated the agency's ban on the botanical, according to a lawsuit filed April 21 by the firm Emord & Associates

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS096449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel